HitGen Inc
SSE:688222

Watchlist Manager
HitGen Inc Logo
HitGen Inc
SSE:688222
Watchlist
Price: 12.07 CNY -7.08% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
HitGen Inc?
Write Note

HitGen Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HitGen Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
HitGen Inc
SSE:688222
Income from Continuing Operations
ÂĄ40.9m
CAGR 3-Years
-14%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Income from Continuing Operations
ÂĄ8.6B
CAGR 3-Years
30%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
15%
CAGR 5-Years
38%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Income from Continuing Operations
ÂĄ3B
CAGR 3-Years
2%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Income from Continuing Operations
ÂĄ1B
CAGR 3-Years
-29%
CAGR 5-Years
7%
CAGR 10-Years
24%
W
WuXi XDC Cayman Inc
HKEX:2268
Income from Continuing Operations
ÂĄ283.5m
CAGR 3-Years
121%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HitGen Inc
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.

Intrinsic Value
7.23 CNY
Overvaluation 40%
Intrinsic Value
Price

See Also

What is HitGen Inc's Income from Continuing Operations?
Income from Continuing Operations
40.9m CNY

Based on the financial report for Dec 31, 2023, HitGen Inc's Income from Continuing Operations amounts to 40.9m CNY.

What is HitGen Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-2%

Over the last year, the Income from Continuing Operations growth was 60%. The average annual Income from Continuing Operations growth rates for HitGen Inc have been -14% over the past three years , -2% over the past five years .

Back to Top